OAKLAND PARK, FL--(Marketwired - December 09, 2014) - Biostem Technologies, Inc. (OTC PINK: BSEM) (BSEM), is pleased to announce the Financial Industry Regulatory Agency (FINRA) has approved a name and symbol change from Caribbean International Holdings, Inc. to Biostem Technologies, Inc. (BSEM) effective today. The new management believes this name will reflect Biostem Technologies, Inc.'s new focus.
Biostem Technologies, Inc. is an emerging Regenerative Medicine company with a vast amount of scientific and clinical knowledge; this knowledge allows (BSEM) to effectively treat patients, explore cutting edge protocols and develop breakthrough treatments. Biostem Technologies, Inc. is focused on evolving the emerging Stem Cell industry with innovative protocols for treatment in an array of rare and common degenerative diseases.
Biostem Technologies, Inc. is also excited to announce its progress on its new interactive website currently in production. This web page will include; but not limited to, a look at our facilities, doctors, and informative articles on stem cell therapy and regenerative medicine. In addition to the website Biostem Technologies, Inc. has launched a new Twitter page (@biostemtech) to help keep the public informed of upcoming news and events.
Biostem Technologies, Inc. management along with Dr. Rafael Gonzalez, will also be attending the 22nd Annual World Congress on Anti-Aging Medicine. The A4M conference is taking place in Las Vegas, NV on December 11-13th. Dr. Gonzalez has become a key opinion leader in the biomedical industry and has expansive knowledge on the behavior and expansion of stem cells and stem cell cryopreservation. His research includes stem cell applications for multiple diseases, degenerative disorders and research on the behavior of stem cell cultures and cell biology from several development stages.
About Cryopreservation & Culture Expansion of Stem Cells:
Mesenchymal stem cells (MSCs) may be isolated from tissues such as adipose, bone marrow, umbilical cord tissue and blood. Following tissue processing, you will have the option of using your mixed cell product, such as stromal vascular fraction or purification of MSCs by expansion in culture. In 2006, there was a set of guidelines defining MSCs. One of the main characteristics is the ability to adhere to plastic. For cells to adhere to plastic, they require culture expanding MSCs and eventual cryopreservation. We will discuss methods of culture expansion and cryopreservation of MSCs. We will overview the use of the reagents necessary to start and expand MSCs. In addition, we will analyze methods of mesenchymal stem cell culture expansion and their implications in patient treatment. We will also discuss the importance and logistics of the cryopreservation process for your expanded MSCs.
About The American Academy of Anti-Aging Medicine (A4M):
The American Academy of Anti-Aging Medicine (A4M) is a US federally registered 501(c) 3 non-profit organization comprised of over 26,000 members including: physicians, health practitioners, scientists, government officials, and members of the general public, representing over 110 nations.
The A4M is dedicated to the advancement of technology to detect, prevent, and treat aging related diseases and to promote research into methods to retard and optimize the human aging process. The A4M is also dedicated to educating physicians, scientist, and members of the public on biomedical sciences, breaking technologies, and anti-aging issues.
About Biostem Technologies, Inc. (BSEM):
Biostem Technologies, Inc. is a holding company for Regenerative Bio Science, Inc. ("RBSI"). The Company subsidiary RBSI is focused on helping individuals protect and ensure their future quality of life through Adult and/or Cord Blood Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic. RBSI's mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies from sports injuries to degenerative diseases such as MS, Arthritis, Degenerative Heart Diseases, Diabetes and a host of experimental therapies in the brain trauma disease sector including CTE. The goal is to become a global leader in establishing protocols that can be patented and utilized to heal patients around the world.
Stem cells work as the repairmen of the body by replenishing and regenerating damaged tissues and cells. Certain conditions have shown marked improvement when treated with stem cells taken from the patient's own body as well as Cord Blood stem cells. Regenerative Bioscience is becoming part of a revolution in healthcare using stem cells.
Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available on at http://www.sec.gov.